

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



B20

(43) International Publication Date
22 November 2001 (22.11.2001)

PCT

(10) International Publication Number
WO 01/87329 A1

(51) International Patent Classification⁷: A61K 38/18, 9/08, 47/02, 47/18

(21) International Application Number: PCT/EP01/05187

(22) International Filing Date: 8 May 2001 (08.05.2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

00110355.5 15 May 2000 (15.05.2000) EP

(71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH];
Grenzacherstrasse 124, CH-4070 Basle (CH).

(72) Inventor: PAPADIMITRIOU, Apollon; Bachstrasse 38a,
83673 Bichl (DE).

(74) Agent: WITTE, Hubert; Grenzacherstrasse 124,
CH-4070 Basle (CH).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CO, CU, CZ, DE, DK,
EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA,
UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/87329 A1

(54) Title: NEW PHARMACEUTICAL COMPOSITION

(57) Abstract: The present invention relates to a liquid pharmaceutical composition comprising an erythropoietin protein, a multiple charged inorganic anion in a pharmaceutically acceptable buffer suitable to keep the solution pH in the range from about 5.5 to about 7.0, and optionally one or more pharmaceutically acceptable excipients. This composition is especially useful for the prophylaxis and treatment of diseases related to erythropoiesis.

New Pharmaceutical Composition

The present invention relates to a liquid pharmaceutical composition comprising an erythropoietin protein, a multiple charged inorganic anion in a pharmaceutically acceptable buffer suitable to keep the solution pH in the range from about 5.5 to about 7.0, and optionally one or more pharmaceutically acceptable excipients. This composition is especially useful for the prophylaxis and treatment of diseases related to erythropoiesis.

Erythropoiesis is the production of red blood cells, which occurs to offset cell destruction. Erythropoiesis is a controlled physiological mechanism that enables sufficient red blood cells to be available for proper tissue oxygenation. Naturally occurring human erythropoietin (hEPO) is produced in the kidney and is the humoral plasma factor which stimulates red blood cell production (Carnot, P and Deflandre, C (1906) C.R. Acad. Sci. 143: 432; Erslev, AJ (1953) Blood 8: 349; Reissmann, KR (1950) Blood 5: 372; Jacobson, LO, Goldwasser, E, Freid, W and Plzak, LF (1957) Nature 179: 6331-4). Naturally occurring EPO stimulates the division and differentiation of committed erythroid progenitors in the bone marrow and exerts its biological activity by binding to receptors on erythroid precursors (Krantz, BS (1991) Blood 77: 419).

Erythropoietin has been manufactured biosynthetically using recombinant DNA technology (Egrie, JC, Strickland, TW, Lane, J et al. (1986) Immunobiol. 72: 213-224) and is the product of a cloned human EPO gene inserted into and expressed in the ovarian

tissue cells of the chinese hamster (CHO cells). The primary structure of the predominant, fully processed form of hEPO is illustrated in SEQ ID NO:1. There are two disulfide bridges between Cys⁷-Cys¹⁶¹ and Cys²⁹-Cys³³. The molecular weight of the polypeptide chain of EPO without the sugar moieties is 18,236 Da. In the intact EPO molecule, 5 approximately 40% of the molecular weight are accounted for by the carbohydrate groups that glycosylate the protein at glycosylation sites on the protein (Sasaki, H, Bothner, B, Dell, A and Fukuda, M (1987) J. Biol. Chem. 262: 12059).

Because human erythropoietin is essential in red blood cell formation, the hormone is useful in the treatment of blood disorders characterized by low or defective red blood 10 cell production. Clinically, EPO is used in the treatment of anemia in chronic renal failure patients (CRF) (Eschbach, JW, Egri, JC, Downing, MR et al. (1987) NEJM 316: 73-78; Eschbach, JW, Abdulhadi, MH, Browne, JK et al. (1989) Ann. Intern. Med. 111: 992; Egrie, JC, Eschbach, JW, McGuire, T, Adamson, JW (1988) Kidney Intl. 33: 262; Lim, VS, Degowin, RL, Zavala, D et al. (1989) Ann. Intern. Med. 110: 108-114) and in AIDS and 15 cancer patients undergoing chemotherapy (Danna, RP, Rudnick, SA, Abels, RI In: MB, Garnick, ed. Erythropoietin in Clinical Applications-An International Perspective. New York, NY: Marcel Dekker; 1990: p. 301-324).

Known pharmaceutical compositions have at least one of the following disadvantages:

20 -they are lyophilisates. Besides the complicated manufacturing procedure, lyophilisates have the disadvantage that they have to be reconstituted before injection into humans. This makes additional handling by medical personnel necessary, which is inconvenient and bears the risk of incorrect handling of the pharmaceutical product;

25 -they contain human serum albumin as an additive. As human serum albumin is a product derived from human body fluid, there is a risk of viral infections by contaminants in the albumin preparation. Also, allergic reactions are possible;

-all presently commercially available erythropoietin compositions are unstable at 30 elevated temperatures, i.e. above refrigerator temperature which is usually between 2 and 8 °C. Therefore, they have to be stored in a refrigerator (2-8 °C) and cannot be stored at room temperature (around 20 °C). This leads to increased costs, caused by storage and shipment at low temperature and also causes inconvenience in handling of the drug product. Unstable in this context means that storage at elevated temperatures, e.g. 25 °C for a prolonged period of time

(i.e. several months, or more than 6 months) leads to degradation of the protein. Degradation in this context describes physical changes (e.g. aggregation or denaturation) and chemical changes (e.g. oxidation or modification of chemical bonds in general) of the protein molecule which are known to occur preferably at elevated temperatures (above 8 °C). Incubating a protein near or above its transition temperature (which is also called melting temperature) leads to unfolding of the protein, i.e. the native structure and the biological activity of the polypeptide is lost. The transition temperature is strongly correlated with the temperature stability of the protein and is dependent on the environment of the protein (e.g. pH, salts, ionic strength, buffer substance, etc.) For example, denaturation may lead to aggregation of erythropoietin molecules, i.e. formation of dimers (covalent or non-covalent), higher order aggregates and even particulates. This leads to reduced potency of the drug and might induce unwanted side effects after injection into humans.

15 The problem underlying the present invention is therefore to provide a composition which is able to minimize or suppress the above mentioned disadvantages.

20 The problem is solved, according to the present invention, by providing a pharmaceutical composition comprising an erythropoietin protein, a multiple charged inorganic anion in a buffer solution of pH of about 5.5 to about 7.0, and optionally one or more pharmaceutically acceptable excipients.

25 It has been surprisingly found that formulating an erythropoietin in this composition improves its stability at temperatures above refrigerator temperature (2-8 °C), especially at room temperature (i.e. below 25 °C) and even at higher temperatures, e.g. 40 °C. This means that the composition can be stored without cooling for a prolonged period of time, without loosing significant amounts of activity and without significant degradation.

Unless otherwise indicated the following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.

30 The term "multiple charged inorganic anion" refers to an inorganic anion having two or more negative charges per molecule, e.g. sulfate SO_4^{2-} , or a phosphate anion, i.e. hydrogenphosphate HPO_4^{2-} . The multiple charged inorganic anion may be added in form

of a corresponding salt, e.g. the sodium salt, the potassium salt and mixtures thereof, and/or in form of the buffer substance, e.g. phosphate buffer.

The term "isoosmolar or isotonic" refers to a solution that can be mixed with body fluids without affecting their constituents. Solutions which are isotonic with blood, such as 5 sodium chloride 0.9%, have the same osmotic pressure as serum and they do not affect the membranes of the red blood cells. In general, solutions which are isotonic with blood are about 290 mosm/kg H₂O.

The term "strong inorganic acid" refers to inorganic acids which show a 20 to 100 % dissociation in a 1 N solution, e.g. H₂SO₄.

10 The term "pharmaceutically acceptable" as used herein means that the buffer or salts are acceptable from a toxicity viewpoint.

The term "diluent" means an ingredient in a medicinal preparation which lacks pharmacological activity but is pharmaceutically necessary or desirable. For example a diluent may be a liquid for the dissolution of drug(s) to be injected, e.g. water.

15 The term "solvents" refers to a liquid that holds another substance in solution, i.e. dissolves it, e.g. water.

The term "preservatives" refers to a substance added to a pharmaceutical composition to prevent bacterial growth, e.g. benzalkonium chloride or benzyl alcohol.

The term "polyol" refers to any substance with multiple hydroxyl groups, including 20 polyhydric alcohols and carbohydrates. The polyhydric alcohols include such compounds as sorbitol, mannitol and glycerol. Carbohydrates are cyclic molecules that may have a keto or aldehyde group, like e.g. sucrose or trehalose.

The term "erythropoietin" or "erythropoietin protein" refers to a protein with the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes 25 and red blood cells and selected from the group consisting of human erythropoietin and analogs which are defined below.

The term "pegylated erythropoietin (Peg-EPO or PEG-EPO)" refers to an erythropoietin protein which is covalently linked with one to three polyethylene derivatives as described below.

The term "device" means a contrivance for a specific purpose. In the present invention the purpose is to enable, support or facilitate administration of the liquid pharmaceutical composition.

Description of Drawings:

5 Figure 1: Primary structure of human EPO (165 amino acids) (SEQ ID NO:1).

Figure 2: Primary structure of human EPO (166 amino acids) (SEQ ID NO:2).

Figure 3: Influence of pH on thermal stability. The transition temperature is plotted against the pH.

10 Figure 4: Influence of ionic strength on thermal stability. The transition temperature is plotted against the phosphate concentration.

Figure 5: Dependence of thermal stability on buffer substance.

Figure 6 shows that sulfate is also a suitable buffer/additive at low pH (e.g. pH 6.2), whereas phosphate is less suitable at pH 6.2 compared to pH 7.5. This shows that sulfate keeps the thermal stability high, even at low pH.

15 Figure 7: Dependency of peg-EPO aggregation on pH. Peg-EPO samples after heat stress (as described above) were analyzed by SDS-PAGE. Proteins were stained with silver. Lane 1: molecular weight standard. Lane 2: pH 5. Lane 3: pH 5, reduced. Lane 4: pH 6. Lane 5: pH 6, reduced. Lane 6: pH 6.5. Lane 7: pH 6.5, reduced. Lane 8: pH 7. Lane 9: pH 7, reduced. Lane 10: peg-EPO, unstressed.

20 Figure 8 shows that the use of 1 mg/ml acetylcysteine as an antioxidant prevents the formation of aggregates under heat stress. Aggregation of pegEPO under heat stress (20 min 80°C): Lane 1: pegEPO at pH 7.5, un-stressed; Lane 2: pegEPO at pH 7.5, stressed; Lane 3: pegEPO at pH 6.2, stressed; Lane 4: pegEPO at pH 6.2, stressed, reduced; Lane 5: pegEPO at pH 7.5, + 1 mg/ml N-Acetyl-cysteine, stressed; Lane 6: pegEPO at pH 7.5, + 1 mg/ml N-Acetyl-cysteine, stressed, reduced

25 Figure 9: Sialic acid (NANA) content of peg-EPO samples in new formulations, stored for six months at various temperatures.

Figure 10: Mouse bioactivity assay of peg-EPO samples after storage in 10 mM sodium phosphate, 40 mM sodium sulfate, 3% (w/v) mannitol, pH 6.2 for 6 months at several temperatures.

Figure 11: Size exclusion chromatogram overlay of peg-EPO samples stored for 6 months in 10 mM sodium phosphate, 40 mM sodium sulfate, 3% (w/v) mannitol, pH 6.2 (bottom to top: buffer, starting material, 4 °C, 25 °C, 30 °C and 40 °C).

In more detail, the present invention relates to a liquid pharmaceutical composition comprising an erythropoietin protein, a multiple charged inorganic anion in a pharmaceutically acceptable buffer suitable to keep the solution pH in the range from about 5.5 to about 7.0 and optionally one or more pharmaceutically acceptable excipients.

In a preferred embodiment, the composition is a liquid solution, e.g. an aqueous solution. In a preferred embodiment of the invention, the above pharmaceutical compositions are isotonic solutions.

The anion is preferably selected from anions of strong inorganic acids, such as H_2SO_4 , H_3PO_4 or citric acid. Accordingly, preferred anions are selected from the group consisting of sulfate, phosphate and citrate, preferably sulfate or phosphate, and most preferably sulfate. The concentration of the multiple charged inorganic anion can vary between 10 and 200 mmol/l, e.g. for the sulfate anion between 10 and 200 mmol/l.

The buffer to be used in the present invention to maintain the pH in the range of about 5.5 to about 7.0, preferably in the range of 5.8 to 6.7, more preferably in the range of 6.0 to 6.5 and most preferably at about pH 6.2 can be conventional buffers of organic or inorganic acids (e.g., phosphate buffer, arginine/ $\text{H}_2\text{SO}_4/\text{Na}_2\text{SO}_4$ buffer, or any other pharmaceutically acceptable buffer system). In a preferred embodiment, the composition comprises a phosphate or an arginine/ $\text{H}_2\text{SO}_4/\text{Na}_2\text{SO}_4$ buffer, more preferably a 10 to 50 mmol/l phosphate buffer. Of course, combinations of these buffer systems are also part of the present invention. The pH value may be adjusted with a corresponding base, e.g. NaOH in the phosphate buffer system and a corresponding acid, e.g. sulfuric acid in the arginine buffer system, respectively.

The compositions of the present invention may comprise one or more pharmaceutically acceptable excipients. These pharmaceutically acceptable excipient may

be selected from pharmaceutically acceptable salts, diluents and/or solvents and/or preservatives, etc., e.g. tonicity agents (isotonic-making agents), polyols, anti-oxidants or non-ionic detergents. Examples for these substances are sodium chloride, calcium chloride, sorbitol, mannitol, glycerol, saccharose, trehalose, acetylcysteine, polysorbate 20, polysorbate 80, or pluronic F68.

In a preferred embodiment of the present invention the pharmaceutical compositions may contain a polyol selected from the group consisting of mannitol, sorbitol, glycerol, trehalose and saccharose, preferably mannitol. The concentration of the polyol can vary between 1 and 10% (w/v).

10 Examples for anti-oxidants are cysteine, methionine, acetylcysteine or ascorbic acid, preferably methionine. Anti-oxidants may usually be added in a concentration between 0.01 and 0.5% (w/v) or, e.g. in the case of methionine in a concentration of 1 – 20 mM.

15 Also, the above described compositions can optionally comprise an isotonic-making agent of from about 0.01 to about 0.9% w/w. These compounds are known in the art; examples for these agents are sodium chloride or sodium sulfate. In a preferred embodiment of the present invention the compositions are isotonic solutions. The above composition may also contain a non-ionic detergent like polysorbate 20, polysorbate 80 or pluronic F 68, preferably pluronic F 68, e.g. up to 1% (w/v), more preferably up to 0.1% (w/v), e.g. 0.001 to 0.01 % (w/v).

20 The above composition may also contain additional salts, e.g. up to 1 mmol/l CaCl_2 .

25 The present invention is especially useful for the preparation of pharmaceutical compositions comprising erythropoietin as pharmaceutically active ingredient. The term "erythropoietin" or "erythropoietin protein" or "EPO" is as follows: particularly the terms refer to a glycoprotein, e.g. the human erythropoietin, e.g. having the amino acid sequence set out in (SEQ ID NO: 1) or (SEQ ID NO: 2) or an amino acid sequence substantially homologous thereto, whose biological properties relate to the stimulation of red blood cell production and the stimulation of the division and differentiation of committed erythroid progenitors in the bone marrow. As used herein, these terms include such proteins modified deliberately, as for example, by site directed mutagenesis or accidentally through mutations. These terms also include analogs having from 1 to 6 additional sites for glycosylation, analogs having at least one additional amino acid at the carboxy terminal end of the glycoprotein, wherein the additional amino acid includes at least one

glycosylation site, and analogs having an amino acid sequence which includes a rearrangement of at least one site for glycosylation. These terms include both natural and recombinantly produced human erythropoietin.

As set out in detail below, the preparation and purification of EPO are well known in the art. By erythropoietin is meant the natural or recombinant protein, preferably human, as obtained from any conventional source such as tissues, protein synthesis, cell culture with natural or recombinant cells. Any protein having the activity of erythropoietin, such as muteins or otherwise modified proteins, is encompassed. Recombinant EPO may be prepared via expression in CHO-, BHK- or HeLa cell lines, by recombinant DNA technology or by endogenous gene activation. Expression of proteins, including, by endogenous gene activation, is well known in the art and is disclosed, for example in U.S. Patents Nos. 5,733,761, 5,641,670, and 5,733,746, and international patent publication Nos. WO 93/09222, WO 94/12650, WO 95/31560, WO 90/11354, WO 91/06667 and WO 91/09955, the contents of each of which are incorporated herein by reference. The preferred EPO species for the preparation of erythropoietin glycoprotein products are human EPO species. More preferably, the EPO species is the human EPO having the amino acid sequence set out in SEQ ID NO:1 or SEQ ID NO:2, more preferably the amino acid sequence SEQ ID NO:1.

Further, erythropoietin may be a glycoprotein analog having from 1 to 6 additional sites for glycosylation. Glycosylation of a protein, with one or more oligosaccharide groups, occurs at specific locations along a polypeptide backbone and greatly affects the physical properties of the protein such as protein stability, secretion, subcellular localization, and biological activity. Glycosylation is usually of two types. O-linked oligosaccharides are attached to serine or threonine residues and N-linked oligosaccharides are attached to asparagine residues. One type of oligosaccharide found on both N-linked and O-linked oligosaccharides is N-acetylneuraminic acid (sialic acid), which is a family of amino sugars containing 9 or more carbon atoms. Sialic acid is usually the terminal residue on both N-linked and O-linked oligosaccharides and, because it bears a negative charge, confers acidic properties to the glycoprotein. Human erythropoietin, having 165 amino acids, contains three N-linked and one O-linked oligosaccharide chains which comprise about 40% of the total molecular weight of the glycoprotein. N-linked glycosylation occurs at asparagine residues located at positions 24, 38, and 83 and O-linked glycosylation occurs at a serine residue located at position 126. The oligosaccharide chains are modified with terminal sialic acid residues. Enzymatic removal of all sialic acid

residues from the glycosylated erythropoietin results in loss of *in vivo* activity but not *in vitro* activity because sialylation of erythropoietin prevents its binding, and subsequent clearance, by hepatic binding protein.

The term "erythropoietin" of the present pharmaceutical composition includes

5 analogs of human erythropoietin with one or more changes in the amino acid sequence of human erythropoietin which result in an increase in the number of sites for sialic acid attachment. These glycoprotein analogs may be generated by site-directed mutagenesis having additions, deletions, or substitutions of amino acid residues that increase or alter sites that are available for glycosylation. Glycoprotein analogs having levels of sialic acid

10 greater than those found in human erythropoietin are generated by adding glycosylation sites which do not perturb the secondary or tertiary conformation required for biological activity. The glycoproteins of the present invention also include analogs having increased levels of carbohydrate attachment at a glycosylation site which usually involve the substitution of one or more amino acids in close proximity to an N-linked or O-linked

15 site. The glycoproteins of the present invention also include analogs having one or more amino acids extending from the carboxy terminal end of erythropoietin and providing at least one additional carbohydrate site. The erythropoietin proteins of the present composition also include analogs having an amino acid sequence which includes a rearrangement of at least one site for glycosylation. Such a rearrangement of glycosylation

20 site involves the deletion of one or more glycosylation sites in human erythropoietin and the addition of one or more non-naturally occurring glycosylation sites. Increasing the number of carbohydrate chains on erythropoietin, and therefore the number of sialic acids per erythropoietin molecules may confer advantageous properties such as increased solubility, greater resistance to proteolysis, reduced immunogenicity, increased serum

25 half-life, and increased biological activity. Erythropoietin analogs with additional glycosylation sites are disclosed in more detail in European Patent Application 640 619, to Elliot published March 1, 1995.

In a preferred embodiment, the pharmaceutical composition of the present invention comprises erythropoietin proteins with an amino acid sequence which includes at least one

30 additional site for glycosylation such as, but not limited to, erythropoietins comprising the sequence of human erythropoietin modified by a modification selected from the following:

Asn³⁰Thr³²;

Asn⁵¹Thr⁵³,

Asn⁵⁷Thr⁵⁹;

Asn⁶⁹;
Asn⁶⁹Thr⁷¹;
Ser⁶⁸Asn⁶⁹Thr⁷¹;
Val⁸⁷Asn⁸⁸Thr⁹⁰;
5 Ser⁸⁷Asn⁸⁸Thr⁹⁰;
Ser⁸⁷Asn⁸⁸Gly⁸⁹Thr⁹⁰;
Ser⁸⁷Asn⁸⁸Thr⁹⁰Thr⁹²;
Ser⁸⁷Asn⁸⁸Thr⁹⁰Ala¹⁶²;
Asn⁶⁹Thr⁷¹Ser⁸⁷Asn⁸⁸Thr⁹⁰;
10 Asn³⁰Thr³²Val⁸⁷Asn⁸⁸Thr⁹⁰;
Asn⁸⁹Ile⁹⁰Thr⁹¹;
Ser⁸⁷Asn⁸⁹Ile⁹⁰Thr⁹¹;
Asn¹³⁶Thr¹³⁸;
Asn¹³⁸Thr¹⁴⁰;
15 Thr¹²⁵; and
Pro¹²⁴Thr¹²⁵.

The notation used herein for modification of amino acid sequence means that the position(s) of the corresponding unmodified protein (e.g. hEPO of SEQ ID NO:1 or SEQ ID NO:2) indicated by the superscripted number(s) is changed to the amino acid(s) that
20 immediately precede the respective superscripted number(s).

The erythropoietin protein may also be an analog having at least one additional amino acid at the carboxy terminal end of the glycoprotein, wherein the additional amino acid includes at least one glycosylation site. The additional amino acid may comprise a peptide fragment derived from the carboxy terminal end of human chorionic
25 gonadotropin. Preferably, the glycoprotein is an analog selected from the group consisting of (a) human erythropoietin having the amino acid sequence, Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln (SEQ ID NO:3), extending from the carboxy terminus; (b) the analog in (a) further comprising Ser⁸⁷ Asn⁸⁸ Thr⁹⁰ EPO; and (c) the analog in (a) further comprising Asn³⁰
30 Thr³² Val⁸⁷ Asn⁸⁸ Thr⁹⁰ EPO.


The erythropoietin protein may also be an analog having an amino acid sequence which includes a rearrangement of at least one site for glycosylation. The rearrangement may comprise a deletion of any of the N-linked carbohydrate sites in human

erythropoietin and an addition of an N-linked carbohydrate site at position 88 of the amino acid sequence of human erythropoietin. Preferably, the glycoprotein is an analog selected from the group consisting of Gln²⁴ Ser⁸⁷ Asn⁸⁸ Thr⁹⁰ EPO; Gln³⁸ Ser⁸⁷ Asn⁸⁸ Thr⁹⁰ EPO; and Gln⁸³ Ser⁸⁷ Asn⁸⁸ Thr⁹⁰ EPO.

5 More particularly, the erythropoietin protein of the present pharmaceutical composition as described above may also include pegylated derivatives thereof. Pegylated derivatives of erythropoietin and their preparation are known in the art and described for example in EP-A-539,167, EP-A-605,963, WO 93/25212, WO 94/20069, WO 95/11924, US Patent No. 5,56, EP-A-584,876, WO 92/16555, WO 94/28024, WO 97/04796, US Pat. Nos. 10 5,359,030 and 5,681,811, US Patent No. 4,179,337, Japanese Patent, WO 98/32466, US Patent No. 5,324,650. A preferred embodiment of pegylated erythropoietin species refer to the derivatives as described below.

Accordingly, the present invention also refers to an erythropoietin conjugate, said conjugate comprising an erythropoietin protein as described above having at least one free 15 amino group and having the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; said erythropoietin being covalently linked 20 to "n" poly(ethylene glycol) groups of the formula $-\text{CO}-(\text{CH}_2)_x-(\text{OCH}_2\text{CH}_2)_m-\text{OR}$ with the $-\text{CO}$ (i.e. carbonyl) of each poly(ethylene glycol) group forming an amide bond with one of said amino groups; wherein R is lower alkyl; x is 2 or 3; m is from about 450 to about 900; n is from 1 to 3; and n and m are chosen so that the molecular weight of the conjugate minus the erythropoietin glycoprotein is from 20 kilodaltons to 100 kilodaltons. 25 This invention further provides pharmaceutical compositions containing conjugates described herein in which the percentage of conjugates in which n is 1 is at least ninety percent, preferably at least ninety-two percent, ore preferably ninety-six percent of all conjugates of the composition.

More specifically the above conjugates may be represented by formula (I)



wherein P is the residue of an erythropoietin protein as described herein, (i.e. without the amino group or amino groups which form an amide linkage with the carbonyl shown in


Formula I), having the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells; and wherein R is lower alkyl; x is 2 or 3; m is from about 450 to about 900; n is from 1 to 3; and n and m are chosen so that the molecular weight of the conjugate minus the erythropoietin glycoprotein is from 20 5 kilodaltons to 100 kilodaltons.

As used herein, "lower alkyl" means a linear or branched alkyl group having from one to six carbon atoms. Examples of lower alkyl groups include methyl, ethyl and isopropyl. In accordance with this invention, R is any lower alkyl. Conjugates in which R is methyl are preferred.

10 The symbol "m" represents the number of ethylene oxide residues (OCH_2CH_2) in the poly(ethylene oxide) group. A single PEG (polyethylene glycol) subunit of ethylene oxide has a molecular weight of about 44 daltons. Thus, the molecular weight of the conjugate (excluding the molecular weight of the EPO) depends on the number "m". In the conjugates of this invention "m" is from about 450 to about 900 (corresponding to a 15 molecular weight of about 20 kDa to about 40 kDa), preferably from about 650 to about 750 (corresponding to a molecular weight of about 30 kDa). The number m is selected such that the resulting conjugate of this invention has a physiological activity comparable to unmodified EPO, which activity may represent the same as, more than, or a fraction of the corresponding activity of unmodified EPO. A molecular weight of "about" a certain 20 number means that it is within a reasonable range of that number as determined by conventional analytical techniques. The number "m" is selected so that the molecular weight of each poly(ethylene glycol) group covalently linked to the erythropoietin glycoprotein is from about 20kDa to about 40kDa, and is preferably about 30 kDa.

In the conjugates of this invention, the number "n" is the number of poly(ethylene 25 glycol) groups covalently bound to free amino groups (including ϵ -amino groups of a lysine amino acid and/or the amino-terminal amino group) of an erythropoietin protein via amide linkage(s). A conjugate of this invention may have one, two, or three PEG groups per molecule of EPO. "n" is an integer ranging from 1 to 3, preferably "n" is 1 or 2, and more preferably "n" is 1. A preferred conjugate of the conjugates described above 30 comprises compounds wherein x is 2, m is 650 to 750, n is 1 and R is methyl.

The compound of formula (I) can be prepared from the known polymeric material:




in which R and m are as described above, by condensing the compound of Formula II with the erythropoietin glycoprotein. Compounds of formula (II) in which x is 3 are alpha-lower alkoxy, butyric acid succinimidyl esters of poly(ethylene glycol) (lower alkoxy-PEG-SBA). Compounds of formula (II) in which x is 2 are alpha-lower alkoxy, propionic acid succinimidyl esters of poly(ethylene glycol) (lower alkoxy-PEG-SPA). Any conventional method of reacting an activated ester with an amine to form an amide can be utilized. In the reaction described above, the exemplified succinimidyl ester is a leaving group causing the amide formation. The use of succinimidyl esters such as the compounds of formula II to produce conjugates with proteins are disclosed in U.S. Patent No. 5,672,662, issued September 30, 1997 (Harris, et al.).

Human EPO contains nine free amino groups, the amino-terminal amino group plus the ϵ -amino groups of 8 lysine residues. When the pegylation reagent was combined with a SBA compound of Formula II, it has been found that at pH 7.5, a protein:PEG ratio of 1:3, and a reaction temperature of from 20-25 °C, a mixture of mono-, di-, and trace amounts of the tri-pegylated species were produced. When the pegylation reagent was a SPA compound of Formula II, at similar conditions except that the protein:PEG ratio was 1:2, primarily the mono-pegylated species is produced. The pegylated EPO can be administered as a mixture, or as the cation exchange chromatography separated different pegylated species. By manipulating the reaction conditions (e.g., ratio of reagents, pH, temperature, protein concentration, time of reaction etc.), the relative amounts of the different pegylated species can be varied.


The pharmaceutical compositions as described above may also contain an erythropoietin protein as defined above having at least one free amino group and having the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have the primary structure of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites; said glycoprotein being covalently linked to from one to three lower-alkoxy poly(ethylene glycol) groups, each poly(ethylene glycol) group being covalently linked to the

glycoprotein *via* a linker of the formula $-\text{C}(\text{O})-\text{X}-\text{S}-\text{Y}-$ with the $\text{C}(\text{O})$ of the linker forming an amide bond with one of said amino groups, X is $-(\text{CH}_2)_k-$ or $-\text{CH}_2(\text{O}-\text{CH}_2-\text{CH}_2)_k-$, k is from 1 to 10, Y is




5 the average molecular weight of each poly(ethylene glycol) moiety is from about 20 kilodaltons to about 40 kilodaltons, and the molecular weight of the conjugate is from about 51 kilodaltons to about 175 kilodaltons.

This erythropoietin species may also be represented by formula (III)




10 wherein R may be any lower alkyl, by which is meant a linear or branched alkyl group having from one to six carbon atoms such as methyl, ethyl, isopropyl, etc. A preferred alkyl is methyl. X may be $-(CH_2)_k-$ or $-CH_2(O-CH_2-CH_2)_k-$, wherein k is from 1 to about 10. Preferably, k is from 1 to about 4, more preferably, k is 1 or 2. Most preferably, X is $-(CH_2)_2$.


15 In Formula 1, Y is



preferably





more preferably




In formula (III), the number m is selected such that the resulting conjugate of formula 5 (III) has a physiological activity comparable to unmodified EPO, which activity may represent the same as, more than, or a fraction of the corresponding activity of unmodified EPO. m represents the number of ethylene oxide residues in the PEG unit. A single PEG subunit of $-(OCH_2CH_2)-$ has a molecular weight of about 44 daltons. Thus, the 10 molecular weight of the conjugate (excluding the molecular weight of the EPO) depends on the number m . A molecular weight of "about" a certain number means that it is within a reasonable range of that number as determined by conventional analytical techniques. m is an integer ranging from about 450 to about 900 (corresponding to a molecular weight of from 20 to 40 kDa), preferably m is from about 550 to about 800 (about 24 to 35 kDa), and most preferably m is from about 650 to about 700 (about 29 to about 31 kDa).

15. In formula (III), the number n is the number of ϵ -amino groups of a lysine amino acid in an erythropoietin protein covalently bound to a PEG unit via an amide linkage. A conjugate of this invention may have one, two, or three PEG units per molecule of EPO. n is an integer ranging from 1 to 3, preferably n is 1 or 2, and more preferably n is 1.

Preferred erythropoietin proteins of formula (III) are represented by the formulae:





Most preferred erythropoietin glycoprotein products are represented by the formula:




wherein in the above formulae n is an integer from 1 to 3; m is an integer from 450 to 900;

5 R is lower alkyl; X is $-(\text{CH}_2)_k-$ or $-\text{CH}_2(\text{O}-\text{CH}_2-\text{CH}_2)_k-$, and P is the residue of the erythropoietin glycoprotein without the amino group or groups which form an amide linkage with X.

Other preferred erythropoietin glycoprotein products are represented by the formulae:



More preferred erythropoietin glycoprotein products are represented by the formula:




These erythropoietin proteins may be prepared by

(a) covalently reacting an ϵ -amino group of a lysine amino acid of an erythropoietin protein represented by the formula, $P-[NH_2]_n$, with a bi-functional reagent represented by the formula, $Z-CO-X-S-Q$, to form an intermediate with an amide linkage represented by the formula:



wherein P is an erythropoietin protein less the amino group which forms an amide linkage; n is an integer ranging from 1 to 3; Z is a reactive group, e.g. a carboxylic-NHS ester; X is $-(CH_2)_k-$ or $-CH_2(O-CH_2-CH_2)_k-$, wherein k is from 1 to about 10; and Q is a protecting group, like alkanoyl, e.g. acetyl.


(b) covalently reacting the intermediate with an amide linkage from step (a) with an activated poly(ethylene glycol) derivative represented by the formula, $W-[OCH_2CH_2]_m-OR$, to form an erythropoietin glycoprotein product represented by the formula:



wherein W is a sulphydryl reactive form of Y ; m is an integer ranging from about 450 to about 900; R is lower alkyl; and Y is as defined above.


In this embodiment, the bi-functional reagent is preferably N-succinimidyl-S-acetylthiopropionate or N-succinimidyl-S-acetylthioacetate, Z is preferably N-hydroxysuccinimide, and the activated poly(ethylene glycol) derivative $W-[OCH_2CH_2]_m-OR$ is preferably selected from the group consisting of iodo-acetyl-methoxy-PEG, methoxy-PEG-vinylsulfone, and methoxy-PEG-maleimide.

In more detail, the erythropoietin proteins of formula (III) may be prepared by covalent linking of thiol groups to EPO ("activation") and coupling the resulting activated EPO with a poly(ethylene glycol) (PEG) derivative. The first step for the preparation of pegylated EPO according to the present invention comprises covalent linking of thiol groups via NH₂-groups of EPO. This activation of EPO is performed with bi-functional reagents which carry a protected thiol group and an additional reactive group, such as active esters (e.g., a succinimidylester), anhydrides, esters of sulphonic acids, halogenides of carboxylic acids and sulphonic acids, respectively. The thiol group is protected by groups known in the art, e.g., acetyl groups. These bi-functional reagents are able to react with the ξ -amino groups of the lysine amino acids by forming an amide linkage. The first step of the reaction is set out below:




EPO, n and X are as defined above and Z is a reactive group known in the art, e.g. a N-hydroxy-succinimide (NHS) substituent of the formula


15




In a preferred embodiment the activation of the ξ -amino lysine groups is performed by reaction with bi-functional reagents having a succinimidyl moiety. The bi-functional reagents may carry different spacer species, e.g. -(CH₂)_k- or -CH₂-(O-CH₂-CH₂)_k- moieties, wherein k is from 1 to about 10, preferably from 1 to about 4, and more preferably 1 or 2, and most preferably 1. Examples of these reagents are N-succinimidyl-S-acetylthiopropionate (SATP) and N-succinimidyl-S-acetylthioacetate (SATA)




Acetylthioalkyl-carboxylic-NHS-ester, like



SATP



SATA

2-(Acetylthio)-(ethoxy)_k-acetic-acid-NHS-ester

with k as defined above.

The preparation of the bi-functional reagents is known in the art. Precursors of 2-(acetylthio)-(ethoxy)_k-acetic-acid-NHS-esters are described in DE-3924705, while the 5 derivatization to the acetylthio compound is described by March, J., Advanced Organic Chemistry, McGraw-Hill, 1977, 375-376. SATA is commercially available (Molecular Probes, Eugene, OR, USA and Pierce, Rockford, IL).


The number of thiol groups to be added to an EPO molecule can be selected by 10 adjusting the reaction parameters, i.e., the protein (EPO) concentration and the protein/bi-functional reagent ratio. Preferably, the EPO is activated by covalently linking from 1 to 5 thiol groups per EPO molecule, more preferably from 1.5 to 3 thiol groups per EPO molecule. These ranges refer to the statistical distribution of the thiol group over the EPO protein population.

The reaction is carried out, for example, in an aqueous buffer solution, pH 6.5-8.0, 15 e.g., in 10 mM potassium phosphate, 50 mM NaCl, pH 7.3. The bi-functional reagent may be added in DMSO. After completion of the reaction, preferably after 30 minutes, the reaction is stopped by addition of lysine. Excess bifunctional reagent may be separated by methods known in the art, e.g., by dialysis or column filtration. The average number of

thiol groups added to EPO can be determined by photometric methods described in, for example, Grasetti, D.R. and Murray, J.F. in *J. Appl. Biochem. Biotechnol.* 119, 41 – 49 (1967).


The above reaction is followed by covalent coupling of an activated poly(ethylene glycol) (PEG) derivative. Suitable PEG derivatives are activated PEG molecules with an average molecular weight of from about 20 to about 40 kDa, more preferably from about 24 to about 35 kDa, and most preferably about 30 kDa.

Activated PEG derivatives are known in the art and are described in, for example, Morpurgo, M. et al. *J. Bioconj. Chem.* (1996) 7, page 363 ff for PEG-vinylsulfone. Linear 10 chain and branched chain PEG species are suitable for the preparation of the compounds of Formula 1. Examples of reactive PEG reagents are iodo-acetyl-methoxy-PEG and methoxy-PEG-vinylsulfone:




The use of these iodo-activated substances is known in the art and described e.g. by 15 Hermanson, G. T. in *Bioconjugate Techniques*, Academic Press, San Diego (1996) p. 147-148.

Most preferably, the PEG species are activated by maleimide using (alkoxy-PEG-maleimide), such as methoxy-PEG-maleimide (MW 30000; Shearwater Polymers, Inc.). The structure of alkoxy-PEG-maleimide is as follows:



with R and m are as defined above, preferably



The coupling reaction with alkoxy-PEG-maleimide takes place after *in situ* cleavage of the thiol protecting group in an aqueous buffer solution, e.g. 10 mM potassium phosphate, 50 mM NaCl, 2 mM EDTA, pH 6.2. The cleavage of the protecting group may be performed, for example, with hydroxylamine in DMSO at 25°C, pH 6.2 for about 90

5 minutes. For the PEG modification the molar ratio of activated EPO/alkoxy-PEG-maleimide should be from about 1:3 to about 1:6, and preferably 1:4. The reaction may be stopped by addition of cysteine and reaction of the remaining thiol (-SH) groups with N-methylmaleimide or other appropriate compounds capable of forming disulfide bonds.

Because of the reaction of any remaining active thiol groups with a protecting group such

10 as N-methylmaleimide or other suitable protecting group, the EPO glycoproteins in the conjugates of this invention may contain such protecting groups. Generally the procedure described herein will produce a mixture of molecules having varying numbers of thiols protected by different numbers of the protecting group, depending on the number of activated thiol groups on the glycoprotein that were not conjugated to PEG-maleimide.

15 Whereas N-methylmaleimide forms the same type of covalent bond when used to block the remaining thiol-groups on the pegylated protein, disulfide compounds will lead in an intermolecular sulfide/disulfide exchange reaction to a disulfide bridged coupling of the blocking reagent. Preferred blocking reagents for that type of blocking reaction are oxidized glutathione (GSSG), cysteine and cystamine. Whereas with cysteine no additional

20 net charge is introduced into the pegylated protein, the use of the blocking reagents GSSG or cystamine results in an additional negative or positive charge.

The further purification of the compounds of formula (III), including the separation of mono-, di- and tri-pegylated EPO species, may be done by methods known in the art, e.g., column chromatography.

25 A composition comprising pegylated erythropoietin derivatives preferably contains at least ninety percent mono-PEG conjugates, i.e. in which n is 1, can be prepared as shown in Example 5. Usually mono-PEG conjugates of erythropoietin glycoproteins are desirable because they tend to have higher activity than di-PEG conjugates. The percentage of mono-PEG conjugates as well as the ratio of mono- and di-PEG species can be controlled

30 by pooling broader fractions around the elution peak to decrease the percentage of mono-PEG or narrower fractions to increase the percentage of mono-PEG in the composition. About ninety percent mono-PEG conjugates is a good balance of yield and activity. Sometimes compositions in which, for example, at least ninety-two percent or at least

ninety-six percent of the conjugates are mono-PEG species (n equals 1) may be desired. In an embodiment of this invention the percentage of conjugates where n is 1 is from ninety percent to ninety-six percent.

Compositions according to the present inventions may comprise 10 to 10000 µg of 5 an erythropoietin protein per ml as defined above. Preferably, the compositions comprise 10 to 1000 µg, e.g. 10, 50, 100, 400, 800 or 2500 µg per ml.

Further, the compositions according to the present invention may comprise 10 µg to 10000 µg erythropoietin protein per ml, 10 – 200 mmol/l sulfate, 10 to 50 mmol/l 10 phosphate, pH 6.0 to 6.5. This composition may also comprise up to 20 mM methionine, 1 – 5 % of a polyol (w/v), up to 0.1 % pluronic F68 (w/v) and optionally up to 1 mM CaCl₂. An example of this composition comprises 10 µg to 10000 µg erythropoietin protein per ml, 40 mmol/l sulfate, 10 mmol/l phosphate, 3% mannitol (w/v), 10 mM methionine, 0.01% pluronic F68 (w/v), pH 6.2.

In a further embodiment of the present invention, the composition may comprise 10 15 µg to 10000 µg erythropoietin protein per ml, 10 to 100 mmol/l NaCl, 10 to 50 mmol/l phosphate pH 6.0 to 7.0, optionally 1-5% (w/v) of a polyol. Further, this composition may comprise up to 20 mM methionine, up to 0.1% pluronic F68 (w/v) and optionally 7.5 µmol/l CaCl₂. Specifically, this composition may comprise 10 µg to 10000 µg 20 erythropoietin protein per ml, 100 mmol/l NaCl, 10 mM methionine, 0.01% pluronic F68 (w/v), and 10 mmol/l phosphate, pH 7.0.

The present invention also refers to the above composition comprising 10 µg to 10000 µg erythropoietin protein per ml, 10 to 50 mmol/l arginine, pH 6 to pH 6.5, 10 to 100 mmol/l sodium sulfate. In addition, this composition may comprise up to 20 mM 25 methionine, up to 0.1% pluronic F68 (w/v), optionally up to 1 mmol/l CaCl₂ and optionally 1 – 5 % (w/v) of a polyol. Specifically, this composition may 10 µg to 10000 µg erythropoietin protein per ml, 40 mmol/l arginine, pH 6.2, 30 mmol/l sodium sulfate, 3 % mannitol (w/v), 10 mM methionine, 0.01% pluronic F68 (w/v) and optionally 1 mmol/l CaCl₂.

A preferred embodiment of the present invention refers to compositions comprising 30 10 to 10000 µg/ml erythropoietin, preferably 25 to 2500 µg/ml erythropoietin, and a) 10 mM sodium/potassium phosphate, 100 mM NaCl, pH 7.0 or b) 10 mM sodium phosphate, 120 mM sodium sulfate, pH 6.2 or

- c) 10 mM sodium phosphate, 40 mM sodium sulfate, 3% mannitol (w/v), pH 6.2 or
- d) 10 mM sodium phosphate, 40 mM sodium sulfate, 3% mannitol (w/v), 10 mM methionine, 0.01% pluronic F68 (w/v), pH 6.2 or
- 5 e) 40 mM arginine, 30 mM sodium sulfate, 3% mannitol (w/v), pH 6.2 or
- f) 40 mM arginine, 30 mM sodium sulfate, 3% mannitol (w/v), 10 mM methionine, 0.01% pluronic F68 (w/v), pH 6.2.

In the most preferred embodiment, the compositions comprise an amount erythropoietin protein of 50, 100, 400, 800 or 2500 µg/ml. The most preferred 10 compositions comprise either 10 mM sodium phosphate, 40 mM sodium sulfate, 3% mannitol (w/v), 10 mM methionine, 0.01% pluronic F68 (w/v), pH 6.2 or 40 mM arginine, 30 mM sodium sulfate, 3% mannitol (w/v), 10 mM methionine, 0.01% pluronic F68 (w/v), pH 6.2.

15 The compositions of the present invention may be in the form of a spray-dried powder.

Further the invention relates to a composition which is a lyophilisate or a spray-dried powder of the compositions as described above. The composition may be re-constituted to form a liquid solution by the addition of a solvent, e.g. water, or applied directly by e.g. an inhalation device or a transdermal application device.

20 The invention also comprises a process for preparing a composition as described above, comprising mixing a erythropoietin protein with a solution comprising a multiple, negatively charged anion and optionally one or more pharmaceutically acceptable excipients as defined above.

In addition, the present invention refers to the use of a composition as defined above 25 for the preparation of medicaments useful for the treatment and prevention of diseases correlated with anemia in chronic renal failure patients (CRF), AIDS and/or for the treatment of cancer patients undergoing chemotherapy. This includes a method for the treatment and prevention of diseases involving anemia in chronic renal failure patients (CRF), AIDS and cancer patients undergoing chemotherapy comprising the step of 30 administering to a patient a composition as defined above.

A further embodiment of the present invention refers to devices for local and systemic sustained release comprising a composition as defined above. This could be any kind of implant that provides a controlled release of erythropoietin comprising the

composition described above, like e.g. polymer-based micro- or nanoparticles. The composition described above can also be provided as a pre-filled syringe or in any other application device, like e.g. a needle-free injection device or an inhalation device.

The composition of this invention can be present as a unit dose for injectable or 5 intravenous administration. On the other hand, the composition of this invention can be stored either in the liquid or solid forms and thereafter divided into unit dosage forms for intravenous or injectable administration. Therefore, the liquid composition of this invention can be present in amounts of as little as 0.3 ml for use as a single dosage form for administration. On the other hand, the volume of the claimed composition can be as large 10 as 60 liters when it is stored prior to distribution in a packaged dosage form. In view of its enhanced stability, the composition of this invention can be stored in large containers so as to be later placed into packaging means suitable for distribution to doctors, patients and hospitals.

The injectable solution of this invention can be administrated by such conventional 15 injection means as syringes which generally allow the administration from 0.3 ml to 20 ml of this composition as a single unit dose. On the other hand, the composition of this invention can be administered by injection utilizing ampuls which contain this composition either as a lyophilisate or as a spray dried powder which is then reconstituted in a conventional manner prior to injection. On the other hand, due to the stability of the 20 compositions of this invention, compositions may be dispensed into unit dosage form such as vials which contain from about 0.3 ml to about 10 ml of this composition. In addition, the compositions of this invention can be administered intravenously utilizing intravenous bags. These bags contain from about 20 ml to about 500 ml of the solution depending upon the period in which the solution is to be administered to a patient. In 25 accordance with this invention, the liquid solution of this invention can be stored in storage containers from which they can be further separated into small dosage form packages for distribution to doctors, hospitals and patients. Due to the stability of the compositions of this invention, these compositions can be stored in such storage containers for long periods of time prior to administration."

30 The preparation of erythropoietin as ingredient for the compositions as described above or as starting point for the preparation of erythropoietin derivatives as described above is described in detail for example in U.S. Patent Nos. 5,547,933 and 5,621,080, EP-B 0 148 605, Huang, S.L., Proc. Natl. Acad. Sci. USA (1984) 2708-2712, EP-B 0 205 564, EP-B

0 209 539 and EP-B 0 411 678 as well as Lai, P.H. et al., *J. Biol. Chem.* 261 (1986) 3116-3121, and Sasaki, H. et al., *J. Biol. Chem.* 262 (1987) 12059-12076. Erythropoietin for therapeutic uses may be produced by recombinant means (EP-B 0 148 605, EP-B 0 209 539 and Egrie, J.C., Strickland, T.W., Lane, J. et al. (1986) *Immunobiol.* 72: 213-224).

5 Methods for the expression and preparation of erythropoietin in serum free medium are described for example in WO 96/35718, to Burg published 14 November 1996, and in European Patent Publication No. 513 738, to Koch published 12 June 1992. In addition to the publications mentioned above, it is known that a serum-free fermentation of recombinant CHO cells which contain an EPO gene can be carried out. Such methods are
10 described for example in EP-A 0 513 738, EP-A 0 267 678 and in a general form by Kawamoto, T. et al., *Analytical Biochem.* 130 (1983) 445-453, EP-A 0 248 656, Kowar, J. and Franek, F., *Methods in Enzymology* 421 (1986) 277-292, Bavister, B., *Expcology* 271 (1981) 45-51, EP-A 0 481 791, EP-A 0 307 247, EP-A 0 343 635, WO 88/00967.

15 In EP-A 0 267 678 an ion exchange chromatography on S-Sepharose, a preparative reverse phase HPLC on a C₈ column and a gel filtration chromatography are described for the purification of EPO produced in serum-free culture after dialysis. In this connection the gel filtration chromatography step can be replaced by ion exchange chromatography on S-Sepharose fast flow. It is also proposed that a dye chromatography on a Blue Trisacryl column be carried out before the ion exchange chromatography.

20 A process for the purification of recombinant EPO is described by Nobuo, I. et al., *J. Biochem.* 107 (1990) 352-359. In this process EPO is treated however with a solution of Tween[®] 20, phenylmethylsulfonyl fluoride, ethylmaleimide, pepstatin A, copper sulfate and oxamic acid prior to the purification steps. Publications, including WO 96/35718, to Burg published 14 November 1996, discloses a process for preparing erythropoietin in a serum free fermentation process (EPOsf).

25 The specific activity of EPO or EPO conjugates in accordance with this invention can be determined by various assays known in the art. The biological activity of the purified EPO proteins of this invention are such that administration of the EPO protein by injection to human patients results in bone marrow cells increasing production of reticulocytes and red blood cells compared to non-injected or control groups of subjects. The biological activity of the EPO proteins, or fragments thereof, obtained and purified in accordance with this invention can be tested by methods according to Annable, et al., *Bull. Wld. Hlth. Org.* (1972) 47: 99-112 and *Pharm. Europa Spec. Issue Erythropoietin BRP Bio*

1997(2). Another biological assay for determining the activity of EPO protein, the normocytthaemic mouse assay, is described in Example 6.

The invention will be better understood by reference to the following examples which illustrate but do not limit the invention described herein.

EXAMPLES**Example 1: Fermentation And Purification Of Human EPO****a) Inoculum Preparation and Fermentation**

5 One vial of the Working Cell Bank, originating from an EPO-producing CHO cell line (ATCC CRL8695, disclosed in EP 411 678 (Genetics Institute) can be used) is taken from the gas phase of the liquid nitrogen storage tank. The cells are transferred into glass spinner flasks and cultivated in a hydrogen carbonate-buffered medium in a humidified CO₂ incubator. Typical serum free media used for the inoculum preparation and

10 fermentation are disclosed in European Patent Application 513 738, to Koch published 12 June 1992, or WO 96/35718, to Burg published 14 November 1996, for example contain as medium DMEM/F12 (e.g. JRH Biosciences/Hazleton Biologics, Denver, US, order No. 57-736) and additionally sodium hydrogencarbonate, L+glutamine, D+glucose, recombinant insulin, sodium selenite, diaminobutane, hydrocortisone, iron(II) sulfate, asparagine, aspartic acid, serine and a stabilizer for mammalian cells such as e.g. polyvinyl alcohol, methyl cellulose, polydextran, poly(ethylene glycol), Pluronic F68, plasma expander polygeline (HEMACCEL[®]) or polyvinyl pyrrolidone (WO 96/35718).

15

20 The cultures are microscopically checked for the absence of contaminating microorganisms, and the cell densities are determined. These tests are performed at each splitting step.

25 After the initial growth period, the cell culture is diluted with fresh medium to the starting cell density and undergoes another growth cycle. This procedure is repeated until a culture volume of approximately 2 l per glass spinner flask has been obtained. After approx. 12 doublings 1 to 5 liter of this culture is available which then is used as inoculum for the 10 l inoculum fermenter.

After 3 - 5 days, the culture in the 10 l fermenter can be used as inoculum for the 100 l inoculum fermenter.

After additional 3 - 5 days of cultivation, the culture in the 100 l fermenter can be used as inoculum for the 1000 l production fermenter.

b) Harvesting and Cell Separation

A batch refeed process is used, i.e. when the desired cell density is reached, approx. 80 % of the culture is harvested. The remaining culture is replenished with fresh culture medium and cultivated until the next harvest. One production run consists of a maximum 5 of 10 subsequent harvests: 9 partial harvests and 1 overall harvest at the end of fermentation. Harvesting takes place every 3 - 4 days.

The determined harvest volume is transferred into a cooled vessel. The cells are removed by centrifugation or filtration and discarded. The EPO containing supernatant of the centrifugation step is in-line filtered and collected in a second cooled vessel. Each 10 harvest is processed separately during purification.

A typical process for the purification of EPO-protein is disclosed in WO 96/35718, to Burg published 14 November 1996. The purification process is explained in the following.

a) Blue Sepharose Chromatography

15 Blue Sepharose (Pharmacia) consists of Sepharose beads to the surface of which the Cibacron blue dye is covalently bound. Since EPO binds more strongly to Blue Sepharose than most non-proteinaceous contaminants, some proteinaceous impurities and PVA, EPO can be enriched in this step. The elution of the Blue Sepharose column is performed by increasing the salt concentration as well as the pH.

20 The column is filled with 80 - 100 l of Blue Sepharose, regenerated with NaOH and equilibrated with equilibration buffer (sodium/ calcium chloride and sodium acetate). The acidified and filtered fermenter supernatant is loaded. After completion of the loading, the column is washed first with a buffer similar to the equilibration buffer containing a higher sodium chloride concentration and consecutively with a Tris-base buffer. The product is 25 eluted with a Tris-base buffer and collected in a single fraction in accordance with the master elution profile.

b) Butyl Toyopearl Chromatography

The Butyl Toyopearl 650 C (Toso Haas) is a polystyrene based matrix to which aliphatic butyl-residues are covalently coupled. Since EPO binds more strongly to this gel than most of the impurities and PVA, it has to be eluted with a buffer containing 5 isopropanol.

The column is packed with 30 - 40 l of Butyl Toyopearl 650 C, regenerated with NaOH, washed with a Tris-base buffer and equilibrated with a Tris-base buffer containing isopropanol.

10 The Blue Sepharose eluate is adjusted to the concentration of isopropanol in the column equilibration buffer and loaded onto the column. Then the column is washed with equilibration buffer with increased isopropanol concentration. The product is eluted with elution buffer (Tris-base buffer with high isopropanol content) and collected in a single fraction in accordance with the master elution profile.

15 c) Hydroxyapatite Ultrogel Chromatography

The Hydroxyapatite Ultrogel (Biosepra) consists of hydroxyapatite which is incorporated in an agarose matrix to improve the mechanical properties. EPO has a low affinity to hydroxyapatite and can therefore be eluted at lower phosphate concentrations than protein impurities.

20 The column is filled with 30 - 40 l of Hydroxyapatite Ultrogel and regenerated with a potassium phosphate/ calcium chloride buffer and NaOH followed by a Tris-base buffer. Then it is equilibrated with a Tris-base buffer containing a low amount of isopropanol and sodium chloride.

25 The EPO containing eluate of the Butyl Toyopearl chromatography is loaded onto the column. Subsequently the column is washed with equilibration buffer and a Tris-base buffer without isopropanol and sodium chloride. The product is eluted with a Tris-base buffer containing a low concentration of potassium phosphate and collected in a single fraction in accordance with the master elution profile.

d) Reversed Phase HPLC on Vydac C4

The RP-HPLC material Vydac C4 (Vydac) consists of silica gel particles, the surfaces of which carry C4-alkyl chains. The separation of EPO from the proteinaceous impurities is 5 based on differences in the strength of hydrophobic interactions. Elution is performed with an acetonitrile gradient in diluted trifluoroacetic acid.

Preparative HPLC is performed using a stainless steel column (filled with 2.8 to 3.2 liter of Vydac C4 silicagel). The Hydroxyapatite Ultrogel eluate is acidified by adding trifluoro-acetic acid and loaded onto the Vydac C4 column. For washing and elution an 10 acetonitrile gradient in diluted trifluoroacetic acid is used. Fractions are collected and immediately neutralized with phosphate buffer. The EPO fractions which are within the IPC limits are pooled.

e) DEAE Sepharose Chromatography

15 The DEAE Sepharose (Pharmacia) material consists of diethylaminoethyl (DEAE) - groups which are covalently bound to the surface of Sepharose beads. The binding of EPO to the DEAE groups is mediated by ionic interactions. Acetonitrile and trifluoroacetic acid pass through the column without being retained. After these substances have been washed off, trace impurities are removed by washing the column with acetate buffer at a low pH. 20 Then the column is washed with neutral phosphate buffer and EPO is eluted with a buffer with increased ionic strength.

The column is packed with DEAE Sepharose fast flow. The column volume is adjusted to assure an EPO load in the range of 3 - 10 mg EPO/ml gel. The column is washed with water and equilibration buffer (sodium/ potassium phosphate). The pooled fractions of 25 the HPLC eluate are loaded and the column is washed with equilibration buffer. Then the column is washed with washing buffer (sodium acetate buffer) followed by washing with equilibration buffer. Subsequently, EPO is eluted from the column with elution buffer (sodium chloride, sodium/ potassium phosphate) and collected in a single fraction in accordance with the master elution profile.

The eluate of the DEAE Sepharose column is adjusted to the specified conductivity. The resulting drug substance is sterile filtered into Teflon bottles and stored at -70 °C.

EXAMPLE 2: Pegylation of EPO with mPEG-SBA

5 EPO purified in accordance with the serum free procedure of Example 1 (EPOsf) was homogeneous as determined by analytical methods and showed the typical isoform pattern consisting of 8 isoforms. It had a specific biological activity of 190,000 IU/mg as determined by the normocytthaemic mouse assay. The pegylation reagent used was a methoxy-PEG-SBA, which is a compound of Formula II in which R is methyl; x is 3; and
10 m is from 650 to 750 (avg. about 680, corresponding to an average molecular weight of about 30 kDa).

Pegylation Reaction

15 To one hundred milligrams of EPOsf (9.71 ml of a 10.3 mg/ml EPOsf stock, 5.48 µmol) 10 ml of 0.1 M potassium phosphate buffer, pH, 7.5 containing 506 mg of 30kDa methoxy-PEG-SBA (16.5 µ mol) (obtained from Shearwater Polymers, Inc., Huntsville, Alabama) was added and mixed for 2h at room temperature (20-23 °C). The final protein concentration was 5 mg/ml and the protein:PEG reagent ratio was 1:3. After two hours, the reaction was stopped by adjusting the pH to 4.5 with glacial acetic acid and
20 stored at -20°C, until ready for purification.

Purification

1. Conjugate Mixture: Approximately 28 ml of SP-SEPHAROSE FF (sulfo-propyl cation exchange resin) was packed into an AMICON glass column (2.2 x 7.5 cm) and equilibrated with 20 mM acetate buffer pH, 4.5 at a flowrate of 150 ml/h. Six milliliters of the reaction mixture containing 30 mg protein was diluted 5-fold with the equilibration buffer and applied onto the column. Unadsorbed materials were washed away with the buffer and the adsorbed PEG conjugate mixture was eluted from the column with 0.175 M NaCl in the equilibration buffer. Unmodified EPOsf still remaining on the column was eluted with 750 mM NaCl. Column was reequilibrated

in the starting buffer. Samples were analyzed by SDS-PAGE and their degree of pegylation were determined. It was found that the 0.175M NaCl eluate contained, mono- as well as di- and trace amounts of the tri-pegylated species, whereas the 750 mM NaCl eluate contained unmodified EPOsf.

5

2. Di-PEG and Mono-PEG-EPOsf: The purified conjugate mixture eluted from the column in the previous step was diluted 4-fold with the buffer and reapplied onto the column and washed as described. Di-PEG-EPOsf and mono-PEG-EPOsf were separately eluted from the column with 0.1M NaCl and 0.175 M NaCl, respectively.

10 Elution was also performed with 750mM NaCl to elute any remaining unmodified EPOsf.

Alternatively, the reaction mixture was diluted 5-fold with the acetate buffer and applied onto the SP-Sepharose column (~0.5 mg protein/ml gel). Column was washed and adsorbed mono-PEG-EPOsf, di-PEG-EPOsf and unmodified EPOsf were eluted as

15 described in the previous section.

Results

PEG-EPOsf was synthesized by chemically conjugating a linear PEG molecule with a number average molecular weight of 30 kDa. PEG-EPOsf was derived from the reaction between the primary amino groups of EPOsf and the succinimidyl ester derivative of a 30 kDa PEG-butyric acid, resulting in an amide bond.

Results are summarized in Table 1. Purified conjugate mixture comprised of mono- and di-PEG-EPOsf and was free of unmodified EPOsf as determined by SDS-PAGE analysis. Conjugate mixture accounted for 23.4 mg or 78% of the starting material. Cation exchange chromatographic separation of mono- and di-PEG-EPOsf indicated that mono- to di-PEG ratio in the conjugate mixture was almost 1:1. After completion of the reaction, ratio of the individual components of Mono: Di: Unmodified were 40: 38: 20 (%). Overall yield was almost quantitative.

TABLE 1: Summary of results of EPOs of pegylation

Sample	Protein (mg)	Yield (%)
Rxn. Mix.	30	100
5 Mono-	12.0	40
10 Di-	11.4	38
10 Unmod.	6.0	20
Conju. Mix.	23.4	78

15

EXAMPLE 3: Pegylation of EPO with mPEG-SPA

A different aliquot of the EPOs of used in Example 2 was reacted with 30 kDa methoxy-PEG-SPA (Shearwater Polymers, Inc., Huntsville, Alabama). Reaction was performed at a protein:reagent ratio of 1:2 and purification techniques were in accordance with Example 2. Primarily the mono-pegylated species was produced.

20

EXAMPLE 4: Covalent Linking of thiol groups to EPO

This example discloses the determination of reaction conditions for the covalent linking of thiol groups to EPO. To determine the conditions, different amounts of a reagent containing a blocked thiol group, here SATA or SATP (dissolved in DMSO ad 10 mg/ml) were added to the EPO solution, here to 1 ml of 5 mg/ml EPO in 10 mM potassium phosphate, 50 mM NaCl, pH 7.3. The reaction was stirred for about 30 minutes (25°C) and stopped by addition of 1 M lysine solution at 10 mM. Excess amounts of SATA and SATP were removed by dialysis against 10 mM potassium phosphate, 50 mM NaCl and 2 mM EDTA, pH 6.2. After removal of the protecting acetyl group with hydroxylamine, the number of thiol groups covalently linked to EPO was determined photometrically with dithiodipyridine according to the method described by Grasetti, D.R. and Murray, J. F. in *J. Appl. Biochem. Biotechnol.* 119, page 41-49 (1967).

The number of thiol groups covalently linked per EPO molecule is shown below.

Molar ratio EPO : SATA or SATP	Mol thiol groups / mol EPO
EPO : SATA = 1 : 3	1,5
EPO : SATA = 1 : 5	2,4
EPO : SATA = 1 : 6	3,2
EPO : SATP = 1 : 3	1,3
EPO : SATP = 1 : 4	2,5
EPO : SATP = 1 : 6	3,7

5 **EXAMPLE 5: Modification of activated EPO with methoxy-PEG-maleimide**

A) Activation of EPO:

100 mg EPO produced according to Example 1 (190,000 IU/ mg as determined by the normocytotoxic mouse assay) were activated with SATA (molar ratio: EPO/SATA = 1/5) according to Example 2. The resulting EPO ("activated EPO") carrying covalently linked blocked thiol groups was separated from by-products like N-hydroxy-succinimide or non-reacted SATA by dialysis as described in Example 1. A solution of 4.5 mg/ml activated EPO in 10 mM potassium phosphate, 50 mM NaCl, 2 mM EDTA, pH 6.2 was obtained.

B) Pegylation of activated EPO:

15 380 mg methoxy-PEG-maleimide having the "most preferred" structure illustrated above (MW 30.000; Shearwater Polymers, Inc., Huntsville (Alabama, USA)) was dissolved in the above solution containing 95 mg activated EPO (4.5 mg/ml in 10 mM potassium phosphate, 50 mM NaCl, 2 mM EDTA, pH 6.2). The resulting molar ratio between activated EPO and methoxy-PEG-maleimide in the solution was 1 : 4. By addition of 1 M 20 aqueous hydroxylamine solution ad 30 mM, pH 6.2 to the above solution the covalently



linked blocked thiol groups of activated EPO were de-blocked. The resulting activated EPO in the reaction mixture of the solution contained free thiol (-SH) groups. De-blocking of the thiol groups was followed immediately by the coupling reaction between the activated EPO now containing free thiol (-SH) groups and methoxy-PEG-maleimide 5 for 90 minutes (stirring, 25°C). The coupling reaction was stopped by addition of 0.2 M aqueous cysteine solution ad 2 mM to the reaction mixture. After 30 minutes excess free thiol groups of the activated EPO which did not react with methoxy-PEG-maleimide were blocked by addition of a 0.5 M N-methylmaleimide solution in DMSO to reach a concentration of 5 mM. After 30 minutes the resulting reaction mixture now containing 10 pegylated EPO species was dialyzed against 10 mM potassium phosphate, pH 7.5 for ≥ 15 hours.

C) Purification of pegylated EPO species:

For separation of the pegylated EPO species from the reaction mixture, the following purification process was performed: A 50 ml Q-Sepharose ff column was equilibrated with 15 10 mM potassium phosphate, pH 7.5. The reaction mixture obtained in step B) was loaded onto the column (flow rate: 3 column volumes (CV) per hour). In order to separate non-reacted methoxy-PEG-maleimide reagent, the column was washed with 5 CV's of 10 mM potassium phosphate, pH 7.5. Pegylated EPO species were separated by elution with an increasing salt gradient consisting of 5 CV's buffer A (10 mM potassium phosphate, pH 20 7.5) and 5 CV's buffer B (10 mM potassium phosphate, 500 mM NaCl, pH 7.5) with a flow rate of 3 CV per hour. Based on the NaCl gradient, the pegylated EPO species (tri-, bi- and mono-pegylated EPO species) were eluted first, followed by the non-pegylated EPO species. The fraction of the eluate containing the pegylated EPO species (tri-, di- and 25 mono-pegylated EPO species) was pooled and filtered (sterile filtration with a 0.2 μ m filter).

Content and purity of tri-, di- and mono-pegylated EPO species were evaluated on Coomassie-stained SDS-PAA gels (Laemmli, Nature 227, 680-685 (1970)) while protein concentrations were measured at 280 nm according the Beer-Lambert law. The apparent molecular weights of the EPO species determined by SDS-PAA electrophoresis were about 30 68 kDa (mono-pegylated EPO species), about 98 kDa (di-pegylated EPO species), and about 128 kDa (tri-pegylated EPO species).

Further separation of the tri-, di and mono-pegylated EPO species can be achieved by chromatography, e.g. by size exclusion chromatography (Superdex, pg 200; Pharmacia). The determination of in-vivo biological activity of the eluate containing tri- di- and mono-pegylated species was performed by the method described below.

5

EXAMPLE 6: In-vivo activity of pegylated EPO determined by the normocytthaemic mouse assay

The normocytthaemic mouse bioassay is known in the art (Pharm. Europa Spec. Issue Erythropoietin BRP Bio 1997(2)) and a method in the monography of erythropoietin of 10 Ph. Eur. BRP. The samples were diluted with BSA-PBS. Normal healthy mice, 7-15 weeks old, were administered s.c. 0.2 ml of the EPO-fraction containing non-pegylated EPO or tri-, di- or mono-pegylated EPO from Example 2 or 3. Over a period of 6 days, blood was drawn by puncture of the tail vein and diluted such that 1 μ l of blood was present in 1 ml of an 0.15 μ mol acridine orange staining solution. The staining time was 3 to 10 minutes. 15 The reticulocyte counts were carried out microfluorometrically in a flow cytometer by analysis of the red fluorescence histogram. The reticulocyte counts were given in terms of absolute figures (per 30,000 blood cells analyzed). For the data presented, each group consisted of 5 mice per day, and the mice were bled only once.

In separate experiments, a single dose of unmodified EPO (25 ng of EPO), the 20 PEG(SBA)-EPO mixture from Example 2 (10 ng of conjugate), mono- and di- pegylated EPOs from Example 2 (10 ng of conjugate), the PEG(SPA)-EPO from Example 3 (10 ng of conjugate), and buffer solution were administered to mice. The results are shown in Table 2. The results show the superior activity and the prolonged half life of the pegylated EPO species indicated by the significantly increased amounts of reticulocytes and the shift of the 25 reticulocytes count maximum using the same dose per mouse (10 ng), compared to a dose of 25 ng for unmodified EPO.

TABLE 2

	EPO (Not modified)	30 kDa SPA PEG	Mono 30K SBA	Di 30K SBA	PEG-EPO SBA Conjugate Mixture	Control Buffer
72 h	1000	1393	1411	994	1328	857
96 h	500	1406	1501	926	1338	697
120 h	~200	1100	1182	791	944	701
144 h	~0	535	607	665	660	708

EXAMPLE 7: Preparation of predominantly mono-PEG-EPO

5 Pegylation Reaction

Starting with 100 mg (5.48 μ mol) of EPOsf in 100 mM potassium phosphate buffer pH 7.5 prepared in accordance with Example 1, there was added 329 mg (10.96 μ mol) of 30 kDa PEG-SBA reagent dissolved in 3ml 1 mM HCL. Enough 100 mM potassium phosphate buffer pH 7.5 was added to make the reaction mixture volume to 20 ml. The 10 final protein concentration was 5 mg/ml and the protein: PEG reagent ratio was 1:2. The reaction mixture was mixed for 2h at ambient temperature (20 - 22°C). After 2h, the reaction was stopped by adjusting the pH to 4.5 with glacial acetic acid and stored frozen at -20°C until ready for purification.

Purification

15 The reaction mixture from the previous step was diluted 1:5 with 10 mM sodium acetate, pH 4.5 and applied to 300 ml SP-Sepharose FF (sulfopropyl cation exchange resin) packed into a 4.2 x 19 cm column. The column was previously equilibrated with the same buffer. Column effluents were monitored at 280 nm with a Gilson UV monitor and recorded with a Kipp and Zonen recorder. The column was washed with 300 ml or 1 bed 20 volume of equilibration buffer to remove excess reagents, reaction byproducts and oligomeric PEG-EPO. It was followed by washing with 2 bed volumes of 100 mM NaCl to remove di-PEG-EPO. Mono-PEG-EPO was then eluted with 200 mM NaCl. During elution of the mono-PEG-EPO, the first 50 ml of the protein peak was discarded and the

mono-PEG-EPO was collected as a 150 ml fraction. Unmodified EPOsf remaining on the column was eluted with 750 mM NaCl. All elution buffers were made in the equilibration buffer. All eluted samples were analyzed by SDS-PAGE and by high performance Size Exclusion Chromatography (SEC). The mono-PEG-EPO pool obtained from the 150 ml fraction, which had no detectable unmodified EPOsf, was then concentrated to ~ 4.5 – 7.5 mg/ml and diafiltered into the storage buffer, 10 mM potassium phosphate, 100 mM NaCl, pH 7.5. Concentration/Diafiltration was performed with Millipore LabscaleTM TFF System fitted with 50 kDa cut off Millipore Pellicon XL Biomax 50 membrane at ambient temperature. Concentrated mono-PEG-EPO was sterile filtered and stored frozen at -10 20°C.

Approximately 75% of EPOsf was pegylated. After purification, total yield was ~30% mono-PEG-EPO with no detectable unmodified EPOsf and around 25% di-PEG-EPO. Oligomers, and unpegylated EPOsf accounted for the remaining protein. The mono-PEG-EPO pool obtained from the 150 ml fraction contained approximately 90% mono-PEG-EPO and approximately 10% di-PEG-EPO.

EXAMPLE 8: Thermostability of EPO and pegylated EPO in various formulations: Analysis by DSC (differential scanning calorimetry)

It is generally accepted that the transition temperature of thermal denaturation measured by differential scanning calorimetry is a valid indicator for the thermostability of proteins. Erythropoietin or pegylated erythropoietin solutions with concentrations between 0.6 and 1.2 mg/ml were analyzed in various buffers with or without stabilizers by means of a Nano-DSC (Calorimetric Sciences Corporation, Utah, USA) at a heating rate of 2 K/min. An increase in transition temperature indicates an increase in thermal stability of the protein. The measured temperature values should not be understood as absolute values but rather represent differences in the stability of the individual formulations relative to one another.

In order to define the optimal pH of the formulation, the pH-dependence of the thermal denaturation of pegylated erythropoietin in the range between 4 and 9 was studied. The protein samples were analyzed in 30 mM Na₂HPO₄, 30 mM sodium citrate, 30 mM borate. Figure 1 shows a plateau of maximal transition temperature between about

pH 6 to about pH 9 and a sharp decrease below pH 5.5. This indicates that the optimal pH for maximal thermal stability lies above pH 5.5. (Fig. 3).

5 In order to investigate the effect of ionic strength, the phosphate concentration dependence of thermal denaturation was determined. Figure 4 shows that the thermal stability increases with an increase in ionic strength of the formulation.

The influence of the buffer substance was also investigated by DSC. From Figure 5 one can see that the most suitable buffers or additives for a high thermal stability are sulfate, citrate or phosphate. Glycine, which is used as a buffer in currently available formulations (see above) is not very suitable.

10 Figure 6 shows that sulfate is also a suitable buffer/additive at low pH (e.g. pH 6.2), whereas phosphate is less suitable at pH 6.2 compared to pH 7.5. This shows that sulfate keeps the thermal stability high, even at low pH. This finding allows a formulation at a pH between 6.0 and 6.5, without severe losses in thermal stability of erythropoietin.

15 EXAMPLE 9: Aggregation of EPO and peg-EPO under thermal stress: Analysis by SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel electrophoresis)

In order to investigate the effect of heat stress on the erythropoietin protein, samples in different formulations were exposed to heat stress (20 min 80 °C) and analyzed by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) under 20 reducing (with DTT in sample buffer) and non-reducing (w/o DTT in sample buffer) conditions. This method allows the detection of covalent aggregate formation. As outlined above, aggregate formation is one of the major degradation pathways of proteins and therefore should be prevented in pharmaceutical formulations of proteins. Aggregates that are detectable in the absence of reducing agent (e.g. DTT) and not detectable in the 25 presence of reducing agent are highly likely to be formed by incorrect disulfide bridging, an oxidation reaction, under heat stress. Figure 5 shows the pH dependency of aggregation under heat stress. This experiment clearly shows that the formation of aggregates is suppressed at a pH below 6.5. The higher the pH, the higher the amount of aggregation. Most of the aggregates that are formed can be reduced by treatment of the samples with a 30 reducing agent during SDS-PAGE, suggesting that a great portion of the aggregates that are formed under heat stress are disulfide-bridged dimers, oligomers and higher order

aggregates. Taken together, this indicates that the formation of aggregates can be prevented to a great extent by keeping the pH of the formulation at or below pH 6.5.

Figure 7: Dependency of peg-EPO aggregation on pH. Peg-EPO samples after heat stress (as described above) were analyzed by SDS-PAGE. Proteins were stained with silver.

5 Lane 1: molecular weight standard. Lane 2: pH 5. Lane 3: pH 5, reduced. Lane 4: pH 6. Lane 5: pH 6, reduced. Lane 6: pH 6.5. Lane 7: pH 6.5, reduced. Lane 8: pH 7. Lane 9: pH 7, reduced. Lane 10: peg-EPO, unstressed.

The formation of aggregates can also be prevented by the use of antioxidants. Figure 8 shows that the use of 1 mg/ml acetylcysteine as an antioxidant prevents the formation of aggregates under heat stress. Therefore, it is useful to use an antioxidant, like e.g. acetylcysteine at a low pH, e.g. pH 6.2, to prevent aggregate formation under heat stress.

Figure 6: Peg-EPO aggregation can be prevented by pH 6.2 and/or acetylcysteine. Peg-EPO samples after heat stress (as described above) were analyzed by SDS-PAGE.

15 Proteins were stained with silver. Lane 1: peg-EPO, unstressed. Lane 2: pH 7.5, stressed. Lane 3: pH 6.2, stressed. Lane 4: pH 6.2, stressed, reduced. Lane 5: pH 7.5, 1 mg/ml acetylcysteine, stressed. Lane 6: pH 7.5, 1 mg/ml acetylcysteine, stressed, reduced.

EXAMPLE 10: Stability of peg-EPO in various formulations at 4, 25, 30 and 40 °C

20 Pegylated EPO in various formulations is incubated at several temperatures. At indicated time points, samples are taken and the stability is assessed by reversed phase high performance chromatography (rpHPLC), high performance size exclusion chromatography (SEC) and sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Table 3 compares the stability of peg-EPO in various formulations at several 25 temperatures. These data clearly show the superiority of the herein enclosed formulations regarding protein recovery and aggregation.

TABLE 3: Stability of peg-EPO in various formulations at several temperatures:

		% recovery after six months at				Aggregation at 30 °C detectable (+/-)
Formulation *	pegEPO (μ g/ml)	4 °C	25 °C	30 °C	40 °C	
A	10	92	91	n.d.	39	n.d.
B	50	97	98	97	78	-
C	50	95	79	79	52	+
E	50	103	102	100	87	-
A	100	96	97	n.d.	50	n.d.
B	400	101	101	101	77	-
C	400	100	94	90	56	+
D	400	98	96	93	73	-
E	400	99	98	100	66	-

*the formulations are:

formulation A: 10 mM sodium phosphate, 100 mM sodium chloride, pH 7.5.

formulation B: 10 mM sodium phosphate, 40 mM sodium sulfate, 3% (w/v) mannitol, pH

5 6.2.

formulation C: 10 mM sodium phosphate, 100 mM NaCl, pH 7.0.

formulation D: 10 mM sodium phosphate, 120 mM sodium sulfate, pH 6.2

formulation E: 40 mM arginine, 30 mM sodium sulfate, 3% mannitol, 1 mM CaCl₂, pH

6.2.

10

EXAMPLE 11: Optimized formulations suppress oxidation of methionine54 in EPO
protein, methionine as an anti-oxidant

15 Pegylated EPO in various formulations is incubated at several temperatures. After 6 months, samples are taken and the degree of methionine54 oxidation is determined, as

follows. Briefly, EPO samples are treated with the endo-proteinase LysC. Resulting peptides are separated by reversed phase chromatography. The ratio of peptide T8oxidized (containing the oxidized methionine54) to peptide T8 (containing non-oxidized methionine54) is calculated. The data are summarized in table 4.

5

TABLE 4: Degree of methionine54 oxidation of EPO protein in various formulations after six months at indicated temperatures

		% oxidized methionine54			
Formulation *	pegEPO (µg/ml)	4 °C	25 °C	30 °C	40 °C
A	400	2.00	15.89	24.89	37.89
B	400	2.33	6.55	12.88	30.24
C	400	2.51	2.95	5.99	14.4
A	50	5.37	21.36	30.62	48.05
B	50	3.44	13.38	16.59	30.83
C	50	4.41	5.52	10.01	15.62

*the formulations are listed below

10 formulation A: 10 mM sodium phosphate, 100 mM sodium chloride, pH 7.0

formulation B: 10 mM sodium phosphate, 40 mM sodium sulfate, 3% (w/v) mannitol, pH 6.2.

formulation C: 10 mM sodium phosphate, 40 mM sodium sulfate, 3% (w/v) mannitol, 1 mM methionine, pH 6.2.

15 These data clearly show that the preferred formulation of the present invention (10 mM sodium phosphate, 40 mM sodium sulfate, 3% (w/v) mannitol, pH 6.2) is superior to other formulations like 10 mM sodium phosphate, 100 mM NaCl, pH 7.0, regarding the degree of methionine54 oxidation. The addition of 1 or 10 mM methionine into the formulation clearly suppresses the oxidation of methionine54. Therefore, methionine acts
20 as an anti-oxidant and stabilizes EPO.

EXAMPLE 12: Sialic acid content of peg-EPO samples in varios formulations

In order to analyze the integrity of the carbohydrate structure of the peg-EPO glycoprotein, the sialic acid content of peg-EPO samples in optimized formulations after storage for 6 months at various temperatures was analyzed by standard techniques. These 5 data show that the integrity of the carbohydrate structure is not negatively influenced by storage of the protein in the new formulations described herein (Figure 9).

EXAMPLE 13: Bioactivity of pegylated EPO after storage at elevated temperature for prolonged time periods

10 In order to proof that storage of peg-EPO in 10 mM sodium phosphate, 40 mM sodium sulfate, 3% (w/v) mannitol, pH 6.2, does not negatively influence bioactivity in vivo, a standard mouse EPO assay was carried out (see Example 6). Peg-EPO samples stored for 6 months in 10 mM sodium phosphate, 40 mM sodium sulfate, 3% (w/v) mannitol, pH 6.2, at the indicated temperatures, showed no loss of in vivo activity after 15 storage at 4, 25 and 30 °C compared to fresh reference standard (Fig. 10).

EXAMPLE 14: Aggregate content of peg-EPO after storage at elevated temperature for 6 months

In order to analyze the aggregate content in peg-EPO samples after storage at 20 elevated temperature in 10 mM sodium phosphate, 40 mM sodium sulfate, 3% (w/v) mannitol, pH 6.2, after 6 months samples where taken and analyzed by size exclusion chromatography.

No aggregates were detectable at 4, 25 and 30 °C, proving the stability of pegylated 25 EPO in the above-mentioned formulations. Figure 11 shows an overlay of the size exclusion chromatogramms.

CLAIMS

1. A liquid pharmaceutical composition comprising an erythropoietin protein, a multiple charged inorganic anion in a pharmaceutically acceptable buffer suitable to keep the solution pH in the range from about 5.5 to about 7.0, and 5 optionally one or more pharmaceutically acceptable excipients.
2. The composition according to claim 1 which is an aqueous solution.
3. The composition according to claims 1 to 2 which is an isotonic solution.
4. The composition according to claims 1 to 3 wherein the anion is an anion of a 10 multiple charged strong inorganic acid.
5. The composition according claims 1 to 4 wherein the anion is selected from the group consisting of sulfate, citrate or phosphate.
6. The composition according to claims 1 to 5 wherein the anion is a sulfate anion.
7. The composition according to claim 6 comprising 10 to 200 mmol/l sulfate.
8. The composition according to claims 1 to 7 wherein the pH is 5.8 to 6.7
9. The composition according to claim 8 wherein the pH is 6.0 to 6.5
10. The composition according to claim 9 the pH is about 6.2.
11. The composition according to claims 1 to 10 wherein the buffer is selected form 15 the group consisting of a phosphate or an arginine/H₂SO₄/Na₂SO₄ buffer.
12. The composition according to claim 11 wherein the buffer is a 10 to 50 mmol phosphate buffer.
13. The composition according claims 1 to 12 wherein the composition comprises 20 one or more pharmaceutically acceptable excipients.
14. The composition according to claim 13 wherein one or more pharmaceutically acceptable excipients are selected form the group consisting of pharmaceutically acceptable salts, diluents, solvents and preservatives.

15. The composition according to claims 13 and 14 wherein the pharmaceutically acceptable excipients are selected from the group consisting of tonicity agents, polyols, anti-oxidants and non-ionic detergents.
16. The composition according to claims 13 to 15 wherein the pharmaceutically acceptable excipient a polyol.
- 5 17. The composition according to claim 16 wherein the polyol is selected from the group consisting of mannitol, sorbitol, glycerol, trehalose and saccharose.
18. The composition according to claim 17 wherein the polyol is mannitol.
19. The composition according to claims 13 to 18 comprising an anti-oxidant.
- 10 20. The composition according to claim 19 wherein the anti-oxidant is methionine.
21. The composition according to claims 13 to 20 comprising up to 1 mmol/l CaCl₂.
22. The composition according to claims 15 to 22 wherein the non-ionic detergent is polysorbate 80, polysorbate 20 or pluronic F68.
- 15 23. The composition according to claim 22 wherein the non-ionic detergent is pluronic F68.
24. The composition according to claims 22 or 23, wherein the composition comprises up to 1% (w/v) of the non-ionic detergent.
25. The composition according to any of claims 22 to 24, wherein the composition comprises up to 0.1% (w/v) of the non-ionic detergent.
- 20 26. The composition according to claims 1 to 25 wherein the erythropoietin protein is a human erythropoietin.
27. The composition according to claim 26 wherein the erythropoietin protein is expressed by endogenous gene activation.
28. The composition according to claims 26 to 27 wherein the erythropoietin protein has the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.
- 25 29. The composition according to claims 26 to 28 wherein the protein has the sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites.

30. The composition according to claims 26 to 28 wherein the erythropoietin protein has the sequence of human erythropoietin modified by a modification selected from the group consisting of:

Asn³⁰Thr³²;
5 Asn⁵¹Thr⁵³;
Asn⁵⁷Thr⁵⁹;
Asn⁶⁹;
Asn⁶⁹Thr⁷¹;
10 Ser⁶⁸Asn⁶⁹Thr⁷¹;
Val⁸⁷Asn⁸⁸Thr⁹⁰;
Ser⁸⁷Asn⁸⁸Thr⁹⁰;
Ser⁸⁷Asn⁸⁸Gly⁸⁹Thr⁹⁰;
15 Ser⁸⁷Asn⁸⁸Thr⁹⁰Thr⁹²;
Ser⁸⁷Asn⁸⁸Thr⁹⁰Ala¹⁶²;
Asn⁶⁹Thr⁷¹Ser⁸⁷Asn⁸⁸Thr⁹⁰;
Asn³⁰Thr³²Val⁸⁷Asn⁸⁸Thr⁹⁰;
20 Asn⁸⁹Ile⁹⁰Thr⁹¹;
Ser⁸⁷Asn⁸⁹Ile⁹⁰Thr⁹¹;
Asn¹³⁶Thr¹³⁸;
Asn¹³⁸Thr¹⁴⁰;
Thr¹²⁵; and
25 Pro¹²⁴Thr¹²⁵.

31. The composition of according to claims 26 to 30, wherein the sequence of human erythropoietin is modified by a rearrangement of at least one glycosylation site.
25

32. The composition of claim 31, wherein the rearrangement comprises deletion of any of the N-linked glycosylation sites in human erythropoietin and addition of an N-linked glycosylation site at position 88 of the sequence of human erythropoietin.

30 33. The composition of claim 31, wherein the glycoprotein has the sequence of human erythropoietin modified by a modification selected from the group consisting of

Gln²⁴Ser⁸⁷Asn⁸⁸Thr⁹⁰;

Gln³⁸ Ser⁸⁷ Asn⁸⁸ Thr⁹⁰; and
Gln⁸³ Ser⁸⁷ Asn⁸⁸ Thr⁹⁰.

34. The composition according to claims 26 to 33, wherein the erythropoietin protein as defined in any of claims is pegylated.

5 35. The composition according to claim 34, wherein the erythropoietin protein is a conjugate, said conjugate comprising an erythropoietin glycoprotein having at least one free amino group and having the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to "n" poly(ethylene glycol) groups of the formula -CO-(CH₂)_x-(OCH₂CH₂)_m-OR with the -CO of each poly(ethylene glycol) group forming an amide bond with one of said amino groups; wherein R is lower alkyl; x is 2 or 3; m is from about 450 to about 900; n is from 1 to 3; and n and m are chosen so that the molecular weight of the conjugate minus the erythropoietin glycoprotein is from 20 kilodaltons to 100 kilodaltons.

15 36. The composition according to claim 35 with an erythropoietin protein of the formula:


20 P-[NHCO-(CH₂)_x-(OCH₂CH₂)_m-OR]_n (I)

wherein m, n, x and R are as above, and P is the residue of the glycoprotein without the n amino group(s) which form amide linkage(s) with the poly(ethylene glycol) group(s).

25 37. The composition according to claim 36, wherein in formula (I) x is 2, m is 650 to 750, n is 1 and R is methyl.

30 38. The composition according to claim 34, wherein the erythropoietin protein is a conjugate, said conjugate comprising an erythropoietin glycoprotein having at least one free amino group and having the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have the primary structure of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites; said glycoprotein being covalently


linked to from one to three lower-alkoxy poly(ethylene glycol) groups, each poly(ethylene glycol) group being covalently linked to the glycoprotein *via* a linker of the formula $-\text{C}(\text{O})\text{-X-S-Y-}$ with the $\text{C}(\text{O})$ of the linker forming an amide bond with one of said amino groups, X is $-(\text{CH}_2)_k-$ or $-\text{CH}_2(\text{O-CH}_2-$ 5 $\text{CH}_2)_k-$, k is from 1 to 10, Y is



the average molecular weight of each poly(ethylene glycol) moiety is from about 20 kilodaltons to about 40 kilodaltons, and the molecular weight of the conjugate is from about 51 kilodaltons to about 175 kilodaltons.

10


39. The conjugate of claim 38, of the formula:



15

wherein n is an integer from 1 to 3; m is an integer from 450 to 900; R is lower alkyl; X is $-(\text{CH}_2)_k-$ or $-\text{CH}_2(\text{O-CH}_2-\text{CH}_2)_k-$, and P is the residue of the erythropoietin glycoprotein without the amino group or groups which form an amide linkage with X .

40. The conjugate of claim 39, of the formula:



5 wherein n is an integer from 1 to 3; m is an integer from 450 to 900; R is lower alkyl; X is $-(CH_2)_k-$ or $-CH_2(O-CH_2-CH_2)_k-$, and P is the residue of the erythropoietin glycoprotein without the amino group or groups which form an amide linkage with X.

41. The composition of claims 1 to 40 comprising 10 μ g to 10000 μ g erythropoietin protein per ml.
42. The composition of claims 1 to 41 comprising 10 μ g to 10000 μ g erythropoietin protein per ml, 10 – 200 mmol/l sulfate, and 10 to 50 mmol/l phosphate pH 6.0 to 10 6.5.
43. The composition of claim 42 comprising up to 20 mM methionine, 1 – 5 % of a polyol (w/v), up to 0.1% pluronic F68 (w/v) and optionally up to 1 mM $CaCl_2$.
44. The composition according to claim 42 or 43 comprising 10 μ g to 10000 μ g erythropoietin protein per ml, 40 mmol/l sulfate, 10 mmol/l phosphate, 3% mannitol (w/v), 10 mM methionine, 0.01% pluronic F68 (w/v), pH 6.2.
45. The composition claims 1 to 41 comprising 10 μ g to 10000 μ g erythropoietin protein per ml, 10 to 100 mmol/l NaCl, 10 to 50 mmol/l phosphate pH 6.0 to 15 7.0, optionally 1-5% of a polyol.
46. The composition of claim 45 up to 20 mM methionine, up to 0.1% pluronic F68 and optionally 7.5 μ mol/l $CaCl_2$.
47. The composition of claim 45 or 46 comprising 10 μ g to 10000 μ g erythropoietin protein per ml, 100 mmol/l NaCl, 10 mM methionine, 0.01% pluronic F68, and 20 10 mmol/l phosphate, pH 7.0.
48. The composition of claims 1 to 41 comprising 10 μ g to 10000 μ g erythropoietin protein per ml, 10 to 50 mmol/l arginine, pH 6 to pH 6.5, 10 to 100 mmol/l sodium sulfate.
49. The composition of claim 48 comprising up to 20 mM methionine, up to 0.1% pluronic F68, optionally up to 1 mmol/l $CaCl_2$ and optionally 1 – 5 % of a polyol.

50. The composition of claims 48 or 49, comprising 10 µg to 10000 µg erythropoietin protein per ml, 40 mmol/l arginine, pH 6.2, 30 mmol/l sodium-sulfate, 3 % mannitol, 10 mM methionine, 0.01% pluronic F68 and optionally 1 mmol/l CaCl₂.
51. The composition according to claims 1 to 41 comprising 25 to 2500 µg/ml erythropoietin and
 - a) 10 mM sodium/potassium phosphate, 100 mM NaCl, pH 7.0 or
 - b) 10 mM sodium phosphate, 120 mM sodium sulfate, pH 6.2 or
 - c) 10 mM sodium phosphate, 40 mM sodium sulfate, 3% mannitol, pH 6.2 or
 - d) 10 mM sodium phosphate, 40 mM sodium sulfate, 3% mannitol, 10 mM methionine, 0.01% pluronic F68, pH 6.2 or
 - e) 40 mM arginine, 30 mM sodium sulfate, 3% mannitol, pH 6.2 or
 - f) 40 mM arginine, 30 mM sodium sulfate, 3% mannitol, 10 mM methionine, 0.01% pluronic F68, pH 6.2.
52. The composition of claims 1 to 51 wherein the amount of erythropoietin is 50, 100, 400, 800 or 2500 µg/ml.
53. The composition of claim 52 comprising 10 mM sodium phosphate, 40 mM sodium sulfate, 3% mannitol, 10 mM methionine, 0.01% pluronic F68, pH 6.2.
54. The composition of claim 52 comprising 40 mM arginine, 30 mM sodium sulfate, 3% mannitol, 10 mM methionine, 0.01% pluronic F68, pH 6.2.
55. The composition of claims 1 to 54 which is a lyophilisate or a spray-dried powder.
56. A process for preparing a composition according to any of claims 1 - 54, comprising mixing a erythropoietin protein with a solution comprising a multiple, negatively charged anion and optionally one or more pharmaceutically acceptable excipients.
57. Use of a composition according to any of claims 1 - 54 for the preparation of medicaments useful for the treatment and prevention of diseases correlated with anemia in chronic renal failure patients (CRF), AIDS and/or for the treatment of cancer patients undergoing chemotherapy.

58. Method for the treatment and prevention of diseases involving anemia in chronic renal failure patients (CRF), AIDS and cancer patients undergoing chemotherapy comprising the step of administering to a patient a composition as claimed in any one of claims 1 to 54.
59. Device for local and systemic sustained release comprising a composition according to any of claims 1 - 54.
60. The invention as hereinbefore described.

- 1/6 -

FIGURES

Figure 1

Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg¹⁰ Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys²⁰
Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala³⁰ Glu His Cys Ser Leu Asn Glu Asn Ile Thr⁴⁰
Val Pro Asp Thr Lys Val Asn Phe Tyr Ala⁵⁰ Trp Lys Arg Met Glu Val Gly Gln Gln Ala⁶⁰
Val Glu Val Trp Gln Gly Leu Ala Leu Leu⁷⁰ Ser Glu Ala Val Leu Arg Gly Gln Ala Leu⁸⁰
Leu Val Asn Ser Ser Gln Pro Trp Glu Pro⁹⁰ Leu Gln Leu His Val Asp Lys Ala Val Ser¹⁰⁰
Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg¹¹⁰ Ala Leu Gly Ala Gln Lys Glu Ala Ile Ser¹²⁰
Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu¹³⁰ Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys¹⁴⁰
Leu Phe Arg Val Tyr Ser Asn Phe Leu Arg¹⁵⁰ Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala¹⁶⁰
Cys Arg Thr Gly Asp¹⁶⁶

Figure 2

Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg¹⁰ Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys²⁰
Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala³⁰ Glu His Cys Ser Leu Asn Glu Asn Ile Thr⁴⁰
Val Pro Asp Thr Lys Val Asn Phe Tyr Ala⁵⁰ Trp Lys Arg Met Glu Val Gly Gln Gln Ala⁶⁰
Val Glu Val Trp Gln Gly Leu Ala Leu Leu⁷⁰ Ser Glu Ala Val Leu Arg Gly Gln Ala Leu⁸⁰
Leu Val Asn Ser Ser Gln Pro Trp Glu Pro⁹⁰ Leu Gln Leu His Val Asp Lys Ala Val Ser¹⁰⁰
Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg¹¹⁰ Ala Leu Gly Ala Gln Lys Glu Ala Ile Ser¹²⁰
Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu¹³⁰ Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys¹⁴⁰
Leu Phe Arg Val Tyr Ser Asn Phe Leu Arg¹⁵⁰ Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala¹⁶⁰
Cys Arg Thr Gly Asp Arg¹⁶⁶

Figure 3




Figure 4




Figure 5





Figure 6



- 4/6 -

Figure 7

1 2 3 4 5 6 7 8 9 10





Figure 8

1 2 3 4 5 6



- 5/6 -

Figure 9




Figure 10





Figure 11



SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

(i) APPLICANT:

- (A) NAME: F.Hoffmann-La Roche AG
- (B) STREET: 124 Grenzacherstrasse
- (C) CITY: Basle
- (E) COUNTRY: Switzerland
- (F) POSTAL CODE (ZIP): CH-4070
- (G) TELEPHONE: (61) 688 11 11
- (H) TELEFAX: (61) 688 13 95
- (I) TELEX: 962 292 hlr ch

15

(ii) TITLE OF INVENTION: New Pharmaceutical Composition

(iii) NUMBER OF SEQUENCES: 2

20

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: WORD
- (D) SOFTWARE: PatentIn Release 2.0

25

<170> PatentIn Ver. 2.0

30

<210> 1

<211> 165

<212> PRT

<213> Homo sapiens

35

<400> 1

Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu
1 5 10 15

40

Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His
20 25 30Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe
35 40 45

45

Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp
50 55 60

50

Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu
65 70 75 80Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp
85 90 95

55

Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu
100 105 110Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala
115 120 125

60

Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val

130 135 140

Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala
145 150 155 160

5 Cys Arg Thr Gly Asp
 165

10 <210> 2
<211> 166
<212> PRT
<213> Homo sapiens

15 <400> 2
Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu
1 5 10 15

20 Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His
20 25 30

25 Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe
35 40 45

30 Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp
50 55 60

Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu
65 70 75 80

35 Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp
85 90 95

40 Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu
100 105 110

Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala
115 120 125

45 Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val
130 135 140

Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala
145 150 155 160

Cys Arg Thr Gly Asp Arg
 165

INTERNATIONAL SEARCH REPORT

Int. Application No.
PCT/EP 01/05187

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K38/18 A61K9/08 A61K47/02 A61K47/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 96 40073 A (ALKERMES) 19 December 1996 (1996-12-19)</p> <p>claims 19-25 page 4, line 13 - line 19 page 5, line 33 -page 6, line 11 page 6, line 28 -page 7, line 15 page 14, line 7 - line 14 example 1 table I</p> <p>—</p> <p style="text-align: center;">-/-</p>	<p>1-27, 41, 42, 45, 51, 52, 55, 56</p>

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

9 October 2001

Date of mailing of the international search report

19/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax (+31-70) 340-3016

Authorized officer

Scarpone, U

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/EP 01/05187

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 171 304 A (CHUGAI SEIYAKU KK,JP) 28 August 1986 (1986-08-28) claims 1,3-7 examples page 1, line 8 - line 18 page 2, line 19 - line 39 ---	1-5, 8-19, 22-27, 41,42, 45,51, 52,55,56
X	EP 0 909 564 A (CHUGAI SEIYAKU KK,JP) 21 April 1999 (1999-04-21) claims page 3, line 5 - line 50 ---	1-5, 8-19,22, 24,26, 27,41, 45,51, 52,55,56
X	US 4 992 419 A (H.WOOG ET AL.) 12 February 1991 (1991-02-12) claims example 5 table 2 ---	1-5, 8-18,21, 22,24, 26,27, 41,45, 51,52, 55,56
X	EP 0 178 665 A (CHUGAI SEIYAKU KK,JP) 23 April 1986 (1986-04-23) claims page 2, line 18 - line 35 tables -----	1-5, 8-19,21, 26,27, 41,45, 51,52, 55,56

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No
PCT/EP 01/05187

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9640073	A	19-12-1996	US	5716644 A	10-02-1998
			AU	705451 B2	20-05-1999
			AU	5972496 A	30-12-1996
			AU	705968 B2	03-06-1999
			AU	6034196 A	30-12-1996
			CA	2223583 A1	19-12-1996
			CA	2223834 A1	19-12-1996
			CZ	9703908 A3	13-05-1998
			EP	0871433 A2	21-10-1998
			EP	0831786 A2	01-04-1998
			JP	11506764 T	15-06-1999
			NZ	309533 A	30-08-1999
			PL	323736 A1	14-04-1998
			WO	9640073 A2	19-12-1996
			WO	9640074 A2	19-12-1996
GB 2171304	A	28-08-1986	FR	2576792 A1	08-08-1986
			JP	2116554 C	06-12-1996
			JP	6072103 B	14-09-1994
			JP	62000032 A	06-01-1987
			US	4732889 A	22-03-1988
EP 909564	A	21-04-1999	AU	722300 B2	27-07-2000
			AU	2407497 A	19-11-1997
			EP	0909564 A1	21-04-1999
			US	6120761 A	19-09-2000
			US	6063734 A	16-05-2000
			WO	9740850 A1	06-11-1997
			JP	3068033 B2	24-07-2000
			JP	10182481 A	07-07-1998
			JP	2000302689 A	31-10-2000
			US	6277367 B1	21-08-2001
US 4992419	A	12-02-1991	DE	3729863 A1	16-03-1989
			AT	77556 T	15-07-1992
			AU	2173988 A	27-04-1989
			CA	1330301 A1	21-06-1994
			CN	1031801 A , B	22-03-1989
			CS	8805901 A2	13-12-1990
			DD	273004 A5	01-11-1989
			DE	3872334 D1	30-07-1992
			DK	483188 A	06-03-1989
			EP	0306824 A2	15-03-1989
			ES	2051806 T3	01-07-1994
			FI	884051 A , B,	06-03-1989
			GR	3005454 T3	24-05-1993
			HK	89495 A	16-06-1995
			HU	47863 A2	28-04-1989
			IE	60310 B	29-06-1994
			IL	87628 A	08-07-1993
			JP	1071818 A	16-03-1989
			JP	2057196 C	23-05-1996
			JP	7080782 B	30-08-1995
			KR	9609929 B1	25-07-1996
			LV	10178 A , B	20-10-1994
			LV	10393 A , B	20-02-1995
			MX	12880 A	01-12-1993
			NO	178687 B	05-02-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte
nal Application No
PCT/EP 01/05187

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
US 4992419	A		NZ 225975 A PH 25618 A PL 274485 A1 PT 88417 A ,B RU 2043118 C1 RU 2100032 C1 ZA 8806528 A	26-07-1991 08-08-1991 17-04-1989 31-07-1989 10-09-1995 27-12-1997 30-05-1989
EP 178665	A	23-04-1986	JP 61097229 A CA 1258629 A1 EP 0178665 A2 US 4806524 A	15-05-1986 22-08-1989 23-04-1986 21-02-1989

THIS PAGE BLANK (USPTO)